Podcasts about google play store

With the international break and Club World Cup right around the corner, FC Cincinnati finally sees the top of the mountain, the halfway point in the season. The next home opponent clocks in after a five-game winless patch, but D.C. United may have been able to figure out their defensive woes. Now, if only Troy Lesesne's team could jump-start their offense... We chat with Gregory Roche from Pitch Pass to get some background on how the dynamic has changed at the District. Is there any insight towards playoff soccer or even a solution in the next transfer window? Does D.C. have a shot at all three points with the leaky FCC defense? And perhaps we spend some time to bond over our exes... Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode 143, which is all about anaphylaxis. This is an important concept to understand since it almost always shows up in sim lab or nursing school exams. Plus, if it does happen to one of your patients, it can be incredibly scary, so quick recognition and action are vital! Anaphylaxis is a life-threatening hypersensitivity reaction that occurs immediately (or shortly after) exposure to an antigen. Because it can quickly be fatal, it's crucial that you understand how to recognize it and intervene immediately. In this podcast episode we'll talk through: What happens in anaphylaxis and anaphylactic shock Why it is potentially fatal The signs/symptoms of anaphylaxis Nursing interventions for anaphylaxis, including medications How to monitor the patient ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Med Surg Solution - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides.  Straight A Nursing App - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. Pharmacology Success Pack - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack.

On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss whether GK coaches should strive for a "perfect" progressive session? Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

For the second home match in a row, FC Cincinnati hosts a Texas squad with a new head coach and a former team superstar. While the Orange & Blue managed to tame Austin FC and Brandon Vazquez last time, the bonds may be tested this time. Former MLS MVP and FCC captain Luciano Acosta comes to town after a difficult offseason breakup and transfer to FC Dallas. We ask Buzz from 3rd Degree to give us a tour of the facilities. Eric Quill's first season as head coach has proven to be a test for Los Toros. After trading away club legend Jesus Ferreira, how does Dallas look now? Are the playoffs and silverware a realistic possibility? Most of all, how well has Lucho integrated into the team dynamic? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Dr. Luis Raez and Michael Reff share the newest update to the medically integrated dispensing pharmacy standards from NCODA and ASCO. They review updates to domain one, on key patient-centered quality standards on health equity and social determinants of health, drug access, patient safety, education, and adherence to maximize treatment outcomes and domain two, on key operational quality standards on logistics, care coordination, and waste prevention. We also cover the impact of these updated standards for clinicians, oncology practices, and people receiving oral anti-cancer medications. Read the complete standards, “Medically Integrated Dispensing Pharmacy: ASCO-NCODA Standards.” Transcript These standards, clinical tools, and resources are available on ASCO.org.  Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice. Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Michael Reff from the Network of Collaborative Oncology Development and Advancement and Dr. Luis Raez from Memorial Cancer Institute and Florida Atlantic University, co-chairs on "Medically Integrated Dispensing Pharmacy: American Society of Clinical Oncology – Network of Collaborative Oncology Development and Advancement Association Standards Update." Thank you for being here, Michael and Dr. Raez. Dr. Luis Raez: Thanks for inviting us. Michael Reff: Thank you for having us. Brittany Harvey: Then, before we discuss these standards, I'd like to note that ASCO takes great care in the development of its standards and ensuring that the ASCO Conflict of Interest policy is followed for each guidance product. The disclosures of potential conflicts of interest for the expert panel, including Michael and Dr. Luis Raez who have joined us here today, are available online with the publication of the standards in JCO Oncology Practice, which is linked in the show notes. So then, to dive into the content here, Michael, I'd like to start with what prompted an update to these ASCO-NCODA standards and what is the scope of this update? Michael Reff: Thank you, Brittany. What led NCODA and ASCO to endeavor in this, and it started back in 2019 as the amount of oral anticancer medications became more and more prevalent in cancer treatment, we saw the need providing a blueprint for excellence in care for patients prescribed oral anticancer medications, specifically in the outpatient setting. And the update was driven by the rapid growth of these oral oncolytics starting back in the mid to late 2015 through 2019 or so, and then continued on into the 2020s where we are today. We saw the increase in the complexity of the management of these patients with these therapies basically outside the traditional clinical settings. And we wanted to make sure that with more cancer treatments that are taken at home than just at the clinic, like in the oral setting, new challenges had emerged around patient safety, access, adherence, and overall treatment success. The updates now address patient-centered and operational interventions designed to improve access, safety, quality, accountability, and outcomes of oral anticancer and other supportive care medications prescribed for the cancer patient. Dr. Luis Raez: As Mike said, these guidelines help improve patient care tremendously, but also help us a lot as an oncologist, you know, community oncologists that- now that we have opportunity to dispense these oral oncolytics, we need help to create our medical integrated pharmacies, and NCODA is providing here a way that, how to do this safely, efficaciously, good quality, you know? So that's why I think we always do everything for the patients, but also this helps a lot to the doctors. And there are a lot of what we call specialty pharmacies or medical integrated pharmacies now nationwide. Michael Reff: I'll build on what Dr. Raez had mentioned. This is the impetus. If you looked at the innovation that was coming from the pharmaceutical companies, many of it coming in the oral form for anticancer medications, and based on that, taking a look at the infrastructure that is in place in these practices, whether it's in the community or the IDN or health system settings, this amount of innovation that was coming needed to be addressed by taking a look at the medically integrated oncology team. And these standards address not just the pharmacy component, but also the whole continuum of care, starting with a medical oncologist or the hematologist, with the pharmacists, nurses, the pharmacy technicians, others that are involved in the care of the patient. And there were no standards involved. And when we approached ASCO back in 2018 to eventually publish the first version of these standards, the need was identified, and we worked collaboratively with ASCO to create the first set and then the revisions as we talked about. One thing to note regarding the revision plus the original standards, we had a cross-section of the care team on the committee, and we did that very purposefully. So, the ASCO-NCODA team curated a committee to help develop these original standards and the revision of these standards with medical oncologists both from community and health systems, pharmacists from both community and health systems, and also nurses. And we also included a patient that currently has and currently receives oral anticancer medication. And so NCODA and ASCO are very proud of the committee that we put together because of the experts in their field, but also extended the invitation to a current patient. And we embedded everybody's expertise in the curation of these standards. Brittany Harvey: Absolutely. I appreciate that background and context and how it's critical to improve patient care. And these standards really help oncologists, and we're looking across the continuum of care to provide optimal care for our patients. So then next, Dr. Raez, I'd like to review the key points of the revised standards for our listeners. So for Domain 1, what are the key patient-centered quality standards on health equity and social determinants of health, drug access, patient safety, education, and adherence to maximize treatment outcomes? Dr. Luis Raez: Yeah, this was a great effort, you know, at the multidisciplinary team. And as you can read in the standard, there were more than 240 publications reviewed; more than 55 of them are quoted here. And the standards are in two groups, as you said. With the group one, I'll briefly mention some of them. For example, SDOH, social determinants of health, is very important because as doctors, we prescribe, and sometimes patients don't get the medication, you know? And we prescribe assuming that 100% of the patients will get the medication. But something simple like the patient doesn't have insurance, the patient is underinsured. I have a patient that we didn't have an address to send the medication because he's homeless. Something that as a doctor you say, "Oh, oh my God, this is outside my realm," but it's not outside reality. So that's why, even if we don't think that this is part of our expertise dealing with social determinants of health, the fact that the patients have food insecurity, they don't have transportation, they don't have insurance, they don't have a caregiver, impact tremendously in the outcomes of the therapy. So that's why, basically, in this standard, we want to call attention that SDOH, social determinants of health, needs to be identified. There are in the literature countless examples of why this is important. For example, in the guidelines, we quote two or three examples of prostate cancer studies that, for example, we quote a study of 27,000 people with prostate cancer that were taking oral oncolytics, and how come the fact that the elderly, seniors, the fact that they have high prescription costs, and how all of this affected the adherence to the medication. And that's why it's important to identify the SDOH. And in other sections of the guidelines, we said how to address them, no? Another important thing in this domain is the cultural, you know, we need to be culturally sensitive and to take care of all of these social factors. For example, here in South Florida, we deal with the Haitian culture, Filipino culture, Latin culture, and American culture, and it's a blend, but it's not easy to go from one to the other. Another one is the fact that we have to include new technologies. A lot of patients, for example, we use EMR, EMR Epic, and now Epic has everything in the phone. The fact that we can have now the patient can see her prescription medication over the phone, the fact that they can use the phone to request from you a refill, and from your phone, you send the refill to the pharmacy, and you notify from your phone to the patient that the refill is sent, and the patient can check in his phone that the refill is ready. These things are amazing because that's why it's important that we incorporate these technologies to the patient care, and in this specific case, of dispensation of oral therapies, no? Another crucial point is education. You cannot be sending a patient a package of 300 pills without education. So that's why in our guidelines, mainly pharmacy, clinical pharmacies, or in some centers like mine, we have advanced practice providers, it's mandatory in our centers to have like a one hour of education before you send the prescription. So the patient is aware about side effects and contraindications, all of these things. They provide them also materials and also consent. You know, in the old times, you don't give chemo without a consent. Now, a lot of people say, "Oh, it's only a pill." There is a lot of benefits or side effects that can come from the pill, so you need to consent everybody, you know? So, another aspect is adherence. I already told about that, but we need to provide patients with a baseline assessment, no? So, you cannot send again the prescription and hope, "Oh, I'll figure it out what happened next month when the patient comes back." I tell you, the patient is homeless, where are you going to send it? If the patient is telling you, "I don't have insurance," what good is it for you to send a prescription? The patient will not get it. So that's why you need to do a baseline assessment of adherence. You need to do a calendar. You need to do electronic support, I mentioned already with the EMR and the phones. For example, my MIP, my specialty pharmacist, sends me a message in the EMR, "Dr. Raez, the insurance is not covering, the patient has a high copayment, we are going to delay the dispensation of the medication." So there needs to be a communication. Or sometimes there is a confusion with the insurance, and I cannot wait for the poor patient to call three, four weeks later, "Oh, I didn't get the medication," to know what happened, no? My MIP is very good. They send the clinical pharmacist a message, "Hey, you know, the insurance doesn't believe that the pill is adequate, or you need to provide more documentation. You need to prove the mutation, the genetic aberration." So if you provide us that, the insurance may approve. So that communication with the doctor is very important to improve adherence. And one important thing that we have in this one that we didn't have in the anterior is the tracking of outside medications. A lot of times you say, "Okay, the insurance allowed us to provide the medication it's 100% responsible." But then the insurance says, "Oh, no, no, don't worry. CVS will provide the medication." So it says, "Well, it's you know, it's not my responsibility. CVS will provide the medication, they have to take care." But we know that outside our specialty pharmacies or MIPs, the care is not very good. So that's why we are taking our ownership that, "Okay, the insurance said the patient will get the medication from some outside pharmacy." But our clinical pharmacists track that. What happened? Did the patient get it? The patient didn't get it. The copayment is still high. So even if you get the medication from somewhere else, if the copayment is high, we, our clinical pharmacists, help the patient to navigate and get the foundation or the copayment or finally the maker, the industry partner, provides the drug for free, but somebody needs to do the paperwork. And that's why this is very important. We cannot abort our responsibility because, "Oh, the insurance said somebody else will give it." I work for the public healthcare system, so my patients, some of them don't have insurance, they are underinsured. So we see these problems every day. And finally, the standards talk about the importance of safety, documentation, verification, monitoring, refills, you know, you need to keep track of refills. We already mentioned how important is the technology to facilitate the refills, and the quality. Brittany Harvey: Yes, thank you for touching on those highlights for Domain 1. It's important that all patients have access to care and these oral anticancer medications, and not only just access to care, but safe and effective care. It's really important, as you mentioned, Dr. Raez, to meet patients where they're at and incorporate technology. And I also want to note the coordination with external pharmacies that you mentioned in tracking outside medications as well. It's not only important for multidisciplinary care within the oncology practice itself, but also external to the oncology practice. That's why we put together this multidisciplinary panel to develop these standards. So then, expanding on that, Dr. Raez, for Domain 2, what are the key operational quality standards? Those on logistics, care coordination, and waste prevention. Dr. Luis Raez: Yeah, we have a lot of standards here, but maybe we can summarize in five or six points, no? For example, financial toxicity in cost and waste are very important because the patients, yeah, you put them on therapy, but as you can understand, if there is disease progression, the patient don't need the medications. And sometimes you get refills even if the patient has disease progression. If you do a dose reduction, the same problem. Or you discontinue medication and the patient keeps getting the drugs. So, you're talking about drugs that are between 20 and 30 thousand dollars per month. This is a lot of money. There are studies that we're quoting in the standards that the waste could be from 1 to 3 or 4 thousand per patient, no? Another aspect is dispensing. When you dispense the medication, this is not as easy as, "I'll ship to your house a bag of medications." You know, there needs to be a diagram, a decision tree. You need to train the staff to know what we're doing. There needs to be an auditing of the process. They need to be even packaging and shipping, you know? For example, I'm in Florida today and outside in summer it's going to be 95 degrees. So, everybody leaves the package outside your house, and sometimes you go the whole day until when you come at 6:00 p.m. There are medications that cannot be left outside there, you know? I don't know, it sounds like a joke, but I have a patient that the medication used to be stolen because people thought that that was something important, you know? And of course, it's important because it's a $20,000 medication. So, the poor patient, because he lives in an area that is not safe, has to come and pick up in person. All of these things sound very trivial, but that's real life that affects adherence. Another important thing is shortage. This is something that we just suffered two or three years ago, and we have to think about what happens in the next shortage. What happens if there's going to be a shortage? What do we do or how are we going to do that? Now we know it's something that is happening probably very soon again, and something that we have to consider. Another standard is the care coordination. You need to have probably, if it's possible, a coordinator. I know that for small practices it's very hard, but for big cancer centers, you should have a coordinator of this. I already mentioned before, the communication between the physicians and the doctors to coordinate the care, no? You need to write the prescription again, you need to provide more information, or to be notified, "Hey, you know, the patient is throwing up in the first week, you need to see the patient, please," no? So, this type of communication needs to exist so we can serve the patient better. It's also important, you know, we're improving quality and we're improving care. It's important to try to collect patient-reported outcomes. This is something that now we have the opportunity, if we do things well, to do it and show that we're providing a better care. The other thing is that we already mentioned SDOH in the other standard. In this standard, we mention mainly SDOH to partner. For example, we collect in my center SDOH, and I always get frustrated when the patient doesn't have transportation. But I didn't know that there are local institutions that provide free Uber rides, free Lyft rides. So that's why it's important to partner with these institutions. I have a local grocery chain that provides free food for the patients, and I didn't know that. It's important to be aware what the patient needs and what resources do you have to fulfill the SDOH. That's the part that we mention in here. So that's why, in summary, those are the six probably most important points here. I'll ask Mike for some comments. Michael Reff: Thank you, Dr. Raez. Brittany, to answer your question, and as was pointed out on logistics, care coordination, and prevention of waste, certainly that is an aspect that has changed in the revision that we're here to talk about. There's really two components to waste, and it's cost avoidance and then waste prevention. And as Dr. Raez mentioned several times, the importance of the medically integrated team and having the ability for that practice to fill that prescription internally and have robust documentation. Cost avoidance is a critical component that the medically integrated pharmacy, or the MIP, can help the total cost of care. And that is by preventing errant fills or waste that can occur by intervening in the care of the cancer patient, as we do every day. But when the practice has access to the medication and can fill that prescription in-house in the medically integrated pharmacy, that team, that care coordination that takes place, can prevent those errant fills or additional fills when there's dose reductions, there's holidays, there's things that happen in real time. And it's impossible for a mail-order pharmacy that's in another state that has lead times, when a prescription needs to be mailed 7 days or 10 days before the patient will run out of the medication, it's impossible for them to logistically coordinate that care like we can internally within the medically integrated pharmacy. So, we prevent waste and overall cost of care by cost avoidance and having that coordination or that continuity of care that we talk about. And we prevent waste from the mail-order pharmacies by taking that prescription internally and filling it, but also doing it in a way that's more sustainable and cost-effective for all stakeholders in the oncology ecosystem. Brittany Harvey: Absolutely. Thank you both for reviewing those key standards for Domain 2 and touching on the importance of distribution logistics and all the things that a medically integrated pharmacy needs to think through in getting oral anticancer agents to patients. Following that, Michael, we've touched on this a little bit earlier, but how will these updated standards impact clinicians and oncology practices? Michael Reff: Yes, and as Dr. Raez and I have discussed throughout this podcast, these additional standards are there to help support that continuity of care by educating the clinicians that are in the oral anticancer medication space to elevate their provision for these oral therapies. What I mean by that is the practice has to perform at a certain level in order for them to, as I call it, deserve the right to fill that prescription by having the processes and procedures in place. And these standards, these updated or revised standards, are the blueprint for better patient care and to help the practices execute on that journey of continuous improvement. Dr. Luis Raez: Yeah, I only want to add, we have practical examples in the guidelines. We quote a couple of studies that have been successful. And this year, for example, I am a lung cancer doctor, we are presenting in World Lung our standards of adherence to oral oncolytics for EGFR therapy, following the NCODA-ASCO standards. We're around 95% of adherence. We are a healthcare system that is public. We have people with no insurance and a lot of social determinants of health. We are trying to show that it's feasible, even in the most difficult circumstance, when you follow the standards, to be successful. Brittany Harvey: Definitely, these standards can help clinicians and oncology practices succeed in providing these medications. So then beyond that, and to wrap us up, Michael, what do these revised standards mean for patients who are receiving oral anticancer medications? Michael Reff: Yes, great point and question, Brittany, because we have covered the benefits to the clinicians and the practices themselves. But how is this going to support better patient care? And it does it in a whole host of ways. I'll cover just a few of them. What I'm about to share with you relates back to what we call at NCODA the "core claims." Like, what's the core claims of having a medically integrated pharmacy within the practice? And there are seven different core claims that we feel practices that are focused on the continuity of care can deliver better outcomes that are embedded in these standards. And it's talking about abandonment, adherence, access and affordability, speed to therapy or time to fill, as we call it, education, patient satisfaction, and cost avoidance that we covered earlier. So those are the core claims that a practice that follows these revised standards can help elevate. So, faster and more affordable access to the oral cancer medications; individualized support to address barriers like transportation, finance, language, or health literacy, and so on; clear, patient-friendly education; something that is near and dear to all clinicians' hearts, and of course, the patient that was on our panel or on our committee, to empower them to manage side effects and recognize when to seek help; and a stronger partnership with a care team, with regular follow-ups focused on their experience, challenges, and successes; and then, greater overall safety through proactive monitoring for medication errors or complications. So all of these aspects, or tenets, as I'll call them, are baked into these quality standards that are totally aligned with NCODA's core claims document that, again, talks about abandonment, adherence, access and affordability, speed to therapy, education, satisfaction for the patients, and also cost avoidance. Dr. Luis Raez: I only want to add and invite the community to adhere to these standards, to practice the standards. You will be providing the best patient care that we can nowadays. Brittany Harvey: Definitely. I think these standards are very important. And Michael, I thank you for touching on those key claims from NCODA. I think those, along with these updated standards, will improve outcomes for patients everywhere. So I want to thank you both so much for your work to update these standards and all the time you put into it. And thank you for your time today too, Michael and Dr. Raez. Michael Reff: I'd like to thank not only the committee, my esteemed committee that helped support the standards and the revision. Many of the original healthcare providers and patient that were on the first go of the standards were part of the second standards. We revised it, of course, and we got additional support from the new committee. And certainly ASCO and their partnership and collaboration with NCODA has been tremendous. And we look forward to the oncology community at large adopting these standards, again, to work together, we do become stronger, and it will improve cancer care for patients receiving oral anticancer medications. So thank you, Brittany. Dr. Luis Raez: I only want to say the same thing. Actually, there is probably more people in NCODA that is not in the publication that has helped. Same in ASCO. Also, we want to give thanks to Dr. Stephen Grubbs, our leader in quality. He's retiring. We're going to miss him, but he has been a key collaborator with Mike organizing these standards for the last five or six years. So, looking forward to these standards in practice. Brittany Harvey: Absolutely. A big thank you to the entire panel and everyone who contributed to this, and NCODA as well. And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the complete standards, go to www.asco.org/standards. I also encourage you to check out the companion episode on these standards on the PQI podcast by NCODA, which you can find on Apple Podcasts and Spotify. You can also find many of our standards and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Over the past few years the cost of living is really biting, with grocery shopping, electricity prices, and fuel prices coming under close scrutiny. Thankfully Pick a pump, a new free app, which is available on the App Store and the Google Playstore will help. Pick a pump compares fuel prices in petrol stations in Northern Ireland, the Republic of Ireland and the UK. Ronan recently caught up with Joel Gray the developer of Pick a pump.Joel talks about his background, how he developed Pick a pump, why Pick a pump has no ads and more.More about Pick a pump:It's a free app that helps drivers compare fuel (petrol/diesel) prices across petrol stations in NI, ROI, and the UK.Some main features include:Station services and contact infoMy Garage section with MOT/NCT infoTraffic WarningsTraffic camera feeds (for premium users in NI)Favourite Stations (premium)eCharger support

With the release of Superman almost upon us, and the dawn of the DCU, we take a look back at every DC film released since the end of the Nolan Batman trilogy, from the DCEU, the other movies that are not in that continuity, and the theatrically animated films, we rank them all (and opinions will vary!) Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Twitter/X, Threads, and Blue Sky feeds: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

The Founders of LOST History Tours joins this episode of Teis Talks as they discuss their passion to share the truth of America's History. The idea emerged from a desire to make rich historical knowledge accessible to everyone, anywhere. Born from a legacy of educators and defenders of religious liberty, the founders of LOST have a passion to ensure America's true history is never LOST. Located at Apple and Google Play Store: https://apps.apple.com/us/app/lost-history-tours/id6740070828 https://play.google.com/store/apps/details?id=com.losthistorytours.app&pcampaignid=web_share&pli=1 To learn more, please visit LOSTHistoryTours.com To learn more about Teis Family Ministries, please visit davidteis.com

Your hygienists are vital for the success of your practice — and you can help them measure their impact! In this episode of Clinical Edge Fridays, Kirk Behrendt brings back Ariel Juday, one of ACT's amazing coaches, to share five KPIs that will help improve efficiency, patient care, and even increase job satisfaction. To learn which metrics your hygienists should track for the health of your patients and practice, listen to Episode 891 of The Best Practices Show!Learn More About Ariel:Send Ariel an email: ariel@actdental.com Follow Ariel on ACT's Instagram: https://www.instagram.com/actdentalSend the ACT Team your questions: info@actdental.com Send Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 891: https://www.youtube.com/@actdental/videosSign up for ACT's BPA to watch Katrina Sanders's Hygiene Exam Essentials Part 1: https://join.actdental.com/users/sign_in?post_login_redirect=https%3A%2F%2Fjoin.actdental.com%2Fc%2Fvideo-recordings%2Fkatrina-sanders-hygiene-exam-essentials-part-1-innovations-in-periodontics#emailSign up for ACT's BPA to watch Katrina Sanders's Hygiene Exam Essentials Part 2:...

#407: Postoperative Pediatric Airway Emergencies Pediatric airway emergencies in the postoperative setting are high-impact events that can quickly escalate to cardiac arrest, so it's vital you recognize and act on them immediately. In this article, you'll review: Unique features of the pediatric airway  Risk factors for postoperative respiratory complications in children Performing a focused pediatric respiratory assessment Signs of respiratory distress in children Common postoperative respiratory complications including desaturation, upper airway obstruction, laryngospasm, bronchospasm, and oversedation/loss of ventilation ___________________ Full Transcript - Read the article and view references Episode 140 - Listen to episode 140 for an overview of pediatric respiratory distress. FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Study Sesh - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  Straight A Nursing App - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. Clinical Success Pack - One of the best ways to fast-track your clinical learning is having the right tools. This FREE pack includes report sheets, sheets to help you plan your day, a clinical debrief form, and a patient safety cheat sheet.  20 Secrets of Successful Nursing Students – Learn key strategies that will help you be a successful nursing student with this FREE guide! Conquering Case Studies - Learn how to approach case studies so they feel less overwhelming while honing your clinical judgment skills in the process.

The last time the Orange & Blue crossed paths with The Five Stripes at TQL Stadium, both teams came out even from a barn-burner of a match. While FC Cincinnati has remained relatively hot, Atlanta United has been trying to reignite their spark, going eight matches winless. The teams intersect paths again on Sunday to finish this season's second leg. What happened to the promise of a high-octane offense and dreams of additions to the trophy case? What can team president Garth Lagerway and head coach Ronny Deila do to reverse course? We sit down with Tommy from Scarves and Spikes to cover Atlanta's major purchases and how they are fitting with the pre-existing roster. More importantly, what's this about a "brisket grilled cheese" being served at the Benz? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the differences of coaching Women GK's vs Men Gk's. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

Welcome back to Major's Mess Hall! In this episode, Gavin and Tony pay tribute to the late George Wendt, reflecting on the legacy of his iconic Cheers character, Norm, and the lasting impact he's had on pop culture. We also dive into the current state of the Marvel Cinematic Universe, sharing our thoughts on upcoming films and whether the franchise still has its spark. Gavin talks about a memorable visit from two friends from Ontario and their adventures around Nova Scotia, while Tony shares a wild—and hilarious—story about helping a man in a wheelchair who may have taken things a step too far. Plus, we give you an exciting update on our business, Siren Rewards—our official app is now live on both the Google Play Store and the Apple App Store! Download it today and help support what we're building.

HR challenges come with running a business. But not every challenge is a nightmare. In this episode of Practical Solutions Day, Kirk Behrendt brings back Alan Twigg, co-owner of Bent Ericksen & Associates, to reveal the most common HR nightmares to worry about and the ones that aren't as bad as they seem. To learn how to prevent and overcome the worst HR nightmares, listen to Episode 890 of The Best Practices Show!Learn More About Alan:Give Alan a call: (800) 679-2760Send Alan an email: alan@bentericksen.com Join Bent Ericksen on Facebook: https://www.facebook.com/BentEricksenAssociatesLearn more about Bent Ericksen: https://bentericksen.comTry Bent Ericksen's HR Director package: https://bentericksen.com/product/hr-directorMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 890: https://www.youtube.com/@actdental/videosMain Takeaways:Unemployment is not a big deal.Scary letters are usually just settlement attempts.Understand what a state labor board investigation entails.Do your due diligence with leave of absence. Don't let it run on.In civil cases, the standard of proof is 50/50. Anything can tip the scale.Document, document, document! It is your golden ticket out of situations.Snippets:0:00 Introduction.1:58 Alan's background.3:42 Why this is an important topic.4:53 Unemployment isn't that big of a deal.11:33 Scary letters are just settlement attempts.15:58 In a civil case, it's 50/50.18:00 The messiness of a labor board investigation.22:29 The importance of documentation.26:01 Final thoughts.27:42 About Bent Ericksen.Alan Twigg...

Send us a textBONE HEALTH REVOLUTION: THE 3-MINUTE SOLUTION FOR LIFELONG STRENGTHIn this eye-opening episode, Dr. Orlena speaks with bone health expert Dr. Tracey Clissold about the "silent epidemic" affecting millions of women and the surprisingly simple solution that takes just minutes a day.Did you know we only have until age 30 to build the skeleton that must last us a lifetime? After that, we begin losing bone density—with losses accelerating dramatically during menopause when women can lose up to 20% of their bone mass in just a few years. This hidden decline puts two-thirds of women at risk for life-altering fractures as they age.The good news? Dr. Clissold reveals her groundbreaking research showing how specific "bone-jarring" movements performed for just 2-3 minutes daily can increase bone density by 3-5%—effectively reversing years of natural bone loss. And contrary to popular belief, walking and most other exercises don't create enough force to stimulate this bone growth.You'll also discover the critical nutritional triad supporting bone health: proper calcium intake (most women only get 70% of what they need), optimal protein consumption for both muscle and bone strength, and the often-overlooked vitamin D connection.Whether you're 30 or 60, this conversation offers actionable strategies to strengthen your skeleton and prevent the devastating fractures that can derail healthy aging. Listen now to transform your bone health in just minutes a day!For more information about the OSTEO-GAINS Bone Health Program, please visit our Website and Instagram. Also, check out our FAQ's and click here to download the OSTEO-GAINS Bone Health App from the Apple Store, or Google Play Store.Join the waitlist for Dr Orlena's Eat Smart System: https://www.drorlena.com/waitlistJoin the free community and enter the competition: https://www.drorlena.com/offers/DeQiSXZp/checkout Podcast Index and Sign up for Weekly Emails: https://www.drorlena.com/blog/index-of-podcasts-and-blog-posts Looking for support? Book a free call with Dr Orlena: https://bookme.name/drorlena/positively-healthy-chat-with-dr-orlena-fb

Welcome to church! Join us for church every Sunday at 9AM and 5PM. --------------------------------------------------------- Are you new to Father's House Church? Follow the link and fill out the form to connect with us: https://bit.ly/3nU5j30 Would you like us to pray with you? Fill out the following form: https://bit.ly/3sYGRkQ Or call us on 086 100 1350. Would you like to join or start a Group? Let us know by filling in the following form: https://bit.ly/groups_ Partner financially with us: https://www.fathershousesa.org/giving/ Listen to our podcast: https://soundcloud.com/fathers-house-sa Connect with us on all our social media platforms @fathershousesa Visit our website at www.fathershousesa.org Download Church Centre Available on both App Store (iOS) and Google Play Store: http://onelink.to/d8qk5r

Wouldn't it be great to predict how much you'll produce this year? There's a way to do it, and it's by tracking this one metric. In this episode of Metric Mondays, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down production per day and how to use it to achieve your production goals. To learn how to stay on track with your daily and annual goals, listen to Episode 889 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email for your Golden Ticket: gina@actdental.com Send Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 889: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Read Atomic Habits by James Clear: https://jamesclear.com/atomic-habitsMain Takeaways:PPD helps identify scheduling patterns and inefficiencies.Track PPD to know if your...

At least twice a year, we circle this day on the calendar. The "Hell Is Real" Derby is upon us, and once again, it's all Ohio. (It always has been.) FC Cincinnati and Columbus Crew have been steadfast and gaining momentum atop the standings, and this weekend's edition presents more than just bragging rights to the victors. We may be biased, but this is the best rivalry in North America, bar none. We know what the Orange & Blue and the Black & Yellow can bring to the table, but what is the vibe from the Crew fans' point of view? How confident are our brethren to the north? We ask Ben and Tre from the Upper 90 Club podcast their opinions on how this season's version of the Crew stands after roster renovations and stadium shakeups. Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Do you want an amazing life with the best work schedule? It can happen! You just need to take time to plan it out. In this episode of Clinical Edge Fridays, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to share the secret to a better schedule and better days at the office. You have more control of your time than you think! To learn how to maximize your time by scheduling smarter, listen to Episode 888 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Gina an email for your Golden Ticket: gina@actdental.com Send Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 888: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Join ACT's BPA to get the Ideal Day Scheduling Guide:...

Welcome to church! Join us for church every Sunday at 9AM and 5PM. --------------------------------------------------------- Are you new to Father's House Church? Follow the link and fill out the form to connect with us: https://bit.ly/3nU5j30 Would you like us to pray with you? Fill out the following form: https://bit.ly/3sYGRkQ Or call us on 086 100 1350. Would you like to join or start a Group? Let us know by filling in the following form: https://bit.ly/groups_ Partner financially with us: https://www.fathershousesa.org/giving/ Listen to our podcast: https://soundcloud.com/fathers-house-sa Connect with us on all our social media platforms @fathershousesa Visit our website at www.fathershousesa.org Download Church Centre Available on both App Store (iOS) and Google Play Store: http://onelink.to/d8qk5r

We are back After A Week Off! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the principles of defending space as a goalkeeper. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

When you hire the wrong people, it costs you more than money. In this episode of Practical Solutions Day, Kirk Behrendt brings back Michelle Wakeman, one of ACT's amazing coaches, to break down three of the biggest mistakes in hiring that you need to avoid. Start choosing the best candidates — not the least worst! To learn the best practices for effective filtering, listen to Episode 887 of The Best Practices Show!Learn More About Michelle:Send Michelle an email: michelle@actdental.com Follow Michelle on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 887: https://www.youtube.com/@actdental/videosLearn more about Bent Ericksen: https://bentericksen.comHiring FAQ's from Bent Ericksen: Bent Ericksen Hiring FAQ.pdfMain Takeaways:Have a clear vision of your ideal candidate.Always perform a pre-interview screening on applicants.Set up a documented, structured interview system for intentional hiring.Spend more time learning about your applicants instead of trying to sell yourself.Never rush to hire out of desperation. Wait for the person who is right for your practice.Snippets:0:00 Introduction.2:10 Why this is an important topic.3:36 Make sure you have a position that needs to be filled.4:59 Choose the best, not the least worst.6:34 Create an efficient system.7:53 One bad apple spoils the bunch.9:40 Perform pre-screenings on...

Send us a textHey Pickles!We hope you're doing well.In this week's Noteworthy segment, we tell you all about a new vegan social app called Connect For Animals. You can get it for free on the Apple App Store or the Google Play Store.You can watch the Unchained TV interview with the creators of the app here: https://www.youtube.com/live/s12mw5x4XoM?si=Ve5c9ez-i5C28gXVOur Main Topic is a rousing game of Vegan Would You Rather! We figured it was time to step away from the world a bit, and just have some fun! We hope you play along. Let us know how you answered!We also have a new vegan restaurant on our Vegan Restaurant SOS series, a Listener Shout Out & More!Thanks so much for listening and for supporting what we do here at Compassion & Cucumbers. We couldn't do it without you, and we wouldn't want to.Love, Sam & ChristineSupport the showJoin Our Patreon https://www.patreon.com/CompassionandcucumbersSign Up For Our Newsletterhttps://www.compassionandcucumbers.comOur YouTube https://www.youtube.com/@compassioncucumbersveganpod/videos72 Reasons To Be Vegan *paid link https://amzn.to/3W8ZwsUVisit Our Website https://www.compassionandcucumbers.comSam's Etsy https://www.etsy.com/shop/CucumberCraftworks

Welcome to church! Join us for church every Sunday at 9AM and 5PM. --------------------------------------------------------- Are you new to Father's House Church? Follow the link and fill out the form to connect with us: https://bit.ly/3nU5j30 Would you like us to pray with you? Fill out the following form: https://bit.ly/3sYGRkQ Or call us on 086 100 1350. Would you like to join or start a Group? Let us know by filling in the following form: https://bit.ly/groups_ Partner financially with us: https://www.fathershousesa.org/giving/ Listen to our podcast: https://soundcloud.com/fathers-house-sa Connect with us on all our social media platforms @fathershousesa Visit our website at www.fathershousesa.org Download Church Centre Available on both App Store (iOS) and Google Play Store: http://onelink.to/d8qk5r

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

On today's episode we get an update on the University of Michigan's plans to start a D1 women's hockey program. We welcome back Jenna Trubiano who was the head coach of the women's club team and is now a strategic advisor to the group working on this project.You can connect with Jenna Trubiano via email trubiano@umich.edu and Jenna's Champs App profile: https://profile.champs.app/h/jenna-trubianoFollow Jenna on X:  @jtribs14 and Instagram:  @jtribs14============================Champs App is your recruiting and development copilot. Champs App helps athletes, coaches, parents and agents/advisors navigate the world of youth sports. Wehave made it easy to create a free Champs App account  where you can add a free, beautiful hockey profile with access to amazing content to help with recruiting and hockey player development.Champs App Messaging is the fast, easy way to send messages to coaches. In addition, you can now track when and how often your email is opened to provide additionalsignal on the level of interest from a coach or school.  ChampsApp Messaging cuts the time to send emails to coaches by over 50%, ensures key information is included and reduces common errors because it has templates that automatically populate the coach's name & email and inserts information from your Champs App profile.  You can also view your sent messages and save personal templates to streamline reusing your personalized messages when emailing coaches.⁠To learn more about Champs App Messaging⁠ please visit: https://www.champs.app/2025/03/champs-app-messaging-2-0/=========================================== Champs App now available iOS and Android in the App Store and Play Store!The mobile apps offer all the same features available in thebrowser version, plus the added convenience of logging in with your Apple or Google credentials. Please note that subscriptions to tools or services must still be completed via a browser, similar to purchasing a book on Amazon Kindle. Download the Champs App mobile app today and take your recruiting and development copilot everywhere you go!Download Champs App for iOS in the Apple App Store hereDownload Champs App for Android in the Google Play Store here=============================CHAMPS+ gives parents and players access to more recruiting & hockey development insights, advice and experts.  With CHAMPS+ you can attend our monthly webinars with an expert covering timely topics during for the recruiting cycle.  Members can submit questions before or during the webinar to be answered by our experts.ChampsGPT, an AI recruiting chatbot specifically optimizedfor women's college recruiting. We put into ChampsGPT all the Champs App podcasts, articles and analysis we've done from the last 4 years including over 100 Champs App podcasts, dozens of articles and deep analysis plus numerous webinars.New articles and videos which includes highly curatedcontent will be added weekly throughout the year, so you can always find fresh, relevant information to help guide you with both recruiting and becoming a better hockey player.So take a tour of CHAMPS+ now – you can see thefull list of articles, videos and events.  You can subscribe to CHAMPS+  on a monthly or a deeply discounted annual basis.  Visit  https://sports.champs.app/champs-plus now and access more recruiting and player development insights, advice and experts for the fraction of the price of an advisor.=========================Here is a list of ⁠2025 Girls Hockey Events⁠:  https://www.champs.app/2024/12/2025-girls-hockey-event-calendar-tournaments-camps-showcases/

Just because you're busy doesn't mean you're productive. In this episode of Metric Mondays, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down scheduled production. By tracking this leading metric, you will create a more strategic schedule that leads to more predictable revenue. Stop scrambling and start strategizing! To learn how to create smoother days for you and your team, listen to Episode 886 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 886: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Main Takeaways:Scheduled production is the first indicator of financial health.Track your future production schedule to strategically create a better week.Low scheduled production leads to last-minute scrambling and stressed-out teams.Run a quick unscheduled treatment report. Reach out to patients to fill high-value slots.Start looking at today and tomorrow's production. It will help you to plan and stay ahead.Snippets:0:00 Introduction.1:11 Scheduled production, explained.2:07 Busy doesn't mean productive.4:04 How this metric impacts the practice.8:24 Countermeasures.11:19 Last thoughts.Miranda Beeson, MS, BSDH...

Do you remember 5-0 at Austin FC in February of 2022? That crushing loss that started the Pat Noonan era at FC Cincinnati? Oh, we all remember. Both teams made the playoffs in 2022, but since then, the Orange & Blue and Los Verdes have inhabited different sides of the coin. While Noonan's boys have managed to stay high, Austin FC has exchanged head coaches after subpar seasons. The greener side of things? Brandon Vazquez has been given one of the keys to the attack atop Austin's revamped offense. So what exactly has Nico Estevez brought to The ATX? We ask Mike and Steph from Moontower Soccer about soccer life under Anthony Precourt, the exchange of designated players in the offseason, the arrival of and the hope of revitalization in the 2025 MLS season. Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Working with kids — and their parents — can be a nightmare. But it doesn't have to be! In this episode of Clinical Edge Fridays, ACT shares their Master Class with Dr. Carla Cohn, founder of Lit Smile Academy. She shares her proven techniques and strategies so you can manage the most difficult cases and effectively perform treatment. Start early, and turn difficult patients into easier, lifelong patients! To stop dreading and start enjoying the kids who come to your practice, listen to Episode 885 of The Best Practices Show!Learn More About Dr. Cohn:Send Dr. Cohn an email: drcohn@shaw.ca Follow Dr. Cohn on Instagram: https://www.instagram.com/kidsdentistcarlaFollow Lit Smile Academy on Instagram: https://www.instagram.com/litsmileacademyRegister for Dr. Cohn's hands-on workshop (June 7, 2025): https://www.litsmileacademy.com/events/lit-smile-vancouverRegister for Lit Smile Cancun (November 15-22, 2025): https://www.litsmileacademy.com/events/litsmilecancunMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 885: https://www.youtube.com/@actdental/videosRead A Work on Operative Dentistry in Two Volumes by Greene Vardiman Black: https://www.google.com/books/edition/A_Work_on_Operative_Dentistry_in_Two_Vol/qr9AAQAAMAAJ?hl=en&gbpv=1Read Wright's Behavior Management in Dentistry for Children, Third Edition:

Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms related to hormone excess, including carcinoid syndrome and carcinoid heart disease, managing symptoms of functioning pancreatic neuroendocrine tumors, and also palliative interventions. Dr. Perez and Del Rivero share how to use this guideline in concert with the systemic therapy for tumor control in metastatic well-differentiated GEP-NETs guideline, and hope for the future for the treatment of gastroenteropancreatic neuroendocrine tumors. Read the full guideline, “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Transcript This guideline, clinical tools, and resources are available on ASCO.org. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in JCO Oncology Practice.        Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Kim Perez from Dana-Farber Cancer Institute and Dr. Jaydira Del Rivero from the Center for Cancer Research at the National Cancer Institute, co-chairs on “Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.” Thank you for being here today, Dr. Del Rivero and Dr. Perez. Dr. Kim Perez: Thank you. Dr. Jaydira Del Rivero: Thank you so much for the invitation. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Perez and Dr. Del Rivero, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to jump into the content here, first Dr. Del Rivero, could you provide an overview of the scope and purpose of this guideline? Dr. Jaydira Del Rivero: Yeah. Thank you so much. Well, first, we really wanted to thank ASCO for allowing us to develop these guidelines for the management of gastroenteropancreatic neuroendocrine tumors. I do want to mention that there is also another set of guidelines that I was very fortunate also to co-chair with Dr. Perez on the systemic management of gastroenteropancreatic neuroendocrine tumors. But when discussing these guidelines as well as with the different panelists, experts in this type of disease, we also realized that the management of these tumors are quite complex, not only from the management of the disease progression, but at the same time, management of the symptoms related to the hormone excess. And because of that, we like to thank ASCO for allowing us to then not only have a discussion on the systemic management of these tumors, but at the same time develop recommendations for the symptoms related to the different hormones that these neuroendocrine tumors may produce. These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms related to hormone excess, such as carcinoid syndrome, carcinoid heart disease, how to manage carcinoid crisis, as well as the different symptoms and how to manage the functional pancreatic neuroendocrine tumors and as well as provide recommendations in the different treatments for these tumor types, not only from the systemic management but also from the surgical management as well as for liver-directed therapy options and the different aspects in terms of the palliative care of these patients to improve not only the symptoms related to the hormone excess caused by these tumors, but as well as to improve the quality of life. Brittany Harvey: Absolutely. And I appreciate that overview. And yes, we'll link the guideline on the Systemic Therapy for Tumor Control for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors in the show notes for our listeners so that they can refer to that companion guideline as well. So then you just described the several different categories of recommendations that this guideline covers on symptom management. So, Dr. Perez, I'd like to start reviewing some of those key recommendations of that guideline. So, starting with what are the key recommendations for carcinoid syndrome and carcinoid heart disease? Dr. Kim Perez: Thank you Brittany. Yeah, I also want to thank ASCO for inviting us to do this podcast today. Just to start, I think these guidelines will really add to what's available in the literature to provide a kind of a quick look for the community provider to manage carcinoid-related symptoms. I think the highlights that I would point out are we've all been using somatostatin analogs for the last few decades to manage symptoms, but with the newer treatments that are now available, we tried to highlight what does the literature support in regards to PRRT, what does the literature support in regards to using systemic therapy for disease management, but also the benefits that you will get from a symptom management perspective using other modalities. I think the highlight really is it's a multidisciplinary approach. We are now considering surgery and embolization or interventional radiology as a critical piece. And I think the third that I'd highlight is the fact that sometimes we get too focused on carcinoid syndrome and the symptoms will actually, may result from other things. And the highlight in the algorithms that we've provided is what other things cause carcinoid-related diarrhea. And let's not forget about that because we will find ourselves treating and patients getting very frustrated with persistence of symptoms when in actuality, we should be treating something else that is causing a very similar symptom. For carcinoid heart disease, I think there are more and more guidelines that are now available to provide guidance there, but I think the major advances are that we should be utilizing heart assessment with echocardiogram with lab values such as BMP. But also critical to this is consulting with our cardiology colleagues and making sure that we're identifying heart related issues that are resulting from hormone excess sooner than later because interventions on the earlier side can really make a significant impact on quality of life and associated comorbidities and mortality. Brittany Harvey: Thank you for reviewing those key points for both carcinoid syndrome and carcinoid heart disease symptom management. So then the next set of recommendations. Dr. Del Rivero, what are the key highlights for symptom management of functioning pancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: Yes, it's very important to recognize the symptoms related to hormone excess due to pancreas neuroendocrine tumors. Up to 10% of pancreas neuroendocrine tumors may produce different hormones. Among those hormones can be insulin, gastrin, glucagon, somatostatin. So it's important to know and understand that based on what a neuroendocrine tumor is, they may produce different types of hormones. The importance of these guidelines is to also recognize some of these symptoms and how to address that, because it's not necessarily in these tumor types besides the management of metastatic disease, and know the different options that we recommend for metastatic disease from the systemic therapy, such as chemotherapy or targeted therapies or PRRT. It's important to recognize the symptoms because based on the symptoms we may recommend a different approach. That's something that is important to acknowledge and recognize. Moreover, in certain functional pancreas neuroendocrine tumors, as Dr. Perez mentioned, is a multidisciplinary approach. And it's important to also discuss these different cases with your endocrinologist. You may need to have an experienced endocrinologist to manage, for example, the excess of insulin. And also discuss your cases with a surgeon and interventional radiologist because some of these approaches can certainly improve the symptoms related to hormone excess. I understand that sometimes medical oncologists in the communities may not have access to the multidisciplinary approach or have the different teams that can manage these tumors, and that's the reason why with these guidelines we wanted to establish the understanding of different symptoms associated with the hormone excess to these neuroendocrine tumors as well as how to manage this. For example, in the case of insulinoma, I think for the medical oncologist it is important to know that the everolimus is an option to be used for these tumors, not only to manage tumor progressions related to this tumor type at the same time, because everolimus as a side effect causes hyperglycemia, that can also improve some of the symptoms related to the excess of insulin besides the somatostatin agonist. I think these recommendations will allow the medical oncologist to recognize the symptoms and based on what the symptoms cause, then you can have a different approach that could be added to the systemic therapies options as well. Brittany Harvey: Yes, beyond systemic therapy, it's important to be recognizing symptoms to provide an individualized approach for every single patient. So then, following that overview of symptom management for functioning pancreatic neuroendocrine tumors, Dr. Perez, what is recommended regarding palliative interventions for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, great question. So I think what's unique to neuroendocrine tumors is that the palliative approach really mirrors what we would be doing for symptom management. Some of these patients are living a very long time with carcinoid related symptoms. And so the approach that we take for the carcinoid symptom control is going to mirror the palliative piece of it. I think for those who develop a burden of disease related symptoms, I think it mirrors what we do across the board for all cancer-related complications. And so I think what we attempted to highlight here and included one of our colleagues who focuses specifically on the field of palliative care and neuroendocrine tumors, was to never really lose sight of what we've been doing to care for symptom management throughout the patient's journey and to always rereview the etiology of the symptoms, ensure that we don't focus solely on carcinoid-related issues, but also the symptom management that we would apply to all patients with cancer-related burden symptoms. Brittany Harvey: Definitely. I think that's a helpful approach to consider when thinking about how to manage these palliative interventions as well. So then Dr. Del Rivero, what should clinicians know as they implement these symptom management recommendations? Dr. Jaydira Del Rivero: Yes, thank you so much for that question. As we have discussed in the last 10 or 15 minutes, we have discussed the different approaches on the management of gastroenteropancreatic neuroendocrine tumors. Clinicians, I think it's important to know that neuroendocrine tumors is a quite complex disease because we're not only addressing the management of tumor growth, but we're also addressing the management of the symptoms related to hormone excess and the complexity associated with that. When medical oncologists or clinicians implement these recommendations it's to understand what symptoms these tumors may cause related to the hormone excess but at the same time, how do we approach those symptoms? As Dr. Perez said that I think is very important is to recognize the different types of diarrhea. It doesn't mean that if the patient has worsening diarrhea, it doesn't mean that this is related to disease progression. So it's important to recognize so that way you can address that, because the type of diarrheas can be related because of the lanreotide or somatostatin agonist, it could be because of the prior surgery. I think it's important to recognize those in order to address the symptom. And the same with the gastroenteropancreatic neuroendocrine tumors. It's important to know what hormones they produce because there are different measurements that may be added to the systemic management of these tumors. I think that there are two aspects here, and that's the reason why these guidelines were implemented in the sense that not only we're going to manage disease progression of these tumors, or how do we manage the metastatic disease of these tumors, but at the same time, how do we manage the symptoms related to the hormone excess and the different complications. Moreover, I think, as we discussed earlier, we need to manage these tumors in a multidisciplinary approach. And something very important is not like one size fits all, because the treatment recommendations, it will depend on different characteristics in terms of the tumor presentations. And hormone excess is one of the important aspects to recognize so that way we can implement these recommendations that will definitely help the quality of life of these patients. Brittany Harvey: Absolutely. And using these guidelines in concert with the systemic therapy guidelines is key. And then beyond this impact for clinicians that Dr. Del Rivero has just outlined, Dr. Perez, what does this new guideline mean for patients with gastroenteropancreatic neuroendocrine tumors? Dr. Kim Perez: Yeah, I think that's an important highlight of this guideline. It really gives patients a voice. I think it recognizes the fact that these symptoms can go unmanaged or mismanaged or just missed, and patients commonly will come in feeling very frustrated and feeling very ill. And I think it will provide them a means to open up a conversation with their providers and say, “Hey, this is what I'm experiencing. Let's talk about what's available. How does this apply to me?” And I think that can be very empowering. I think it's really hard nowadays with so many sources and resources online and patients are really left wondering what are the bullet points that they should be bringing to their clinician appointments? And I think that these guidelines provide them a good framework for those discussions. Brittany Harvey: Yes, bringing these discussion points for patients is very important to be able to have those resources. And we have some patient resources and information available on the website for this guideline and we can link that in the show notes for listeners. So then you've both touched on the importance of this guideline for improving quality of life and we continue to see advancements in this field. So Dr. Del Rivera, what are the outstanding questions regarding symptom management and tumor control for gastroenteropancreatic neuroendocrine tumors? Dr. Jaydira Del Rivero: I have to say whenever somebody asks me that question, the word that I will say is I feel hopeful, because more than 10 years ago we didn't have that many options for gastroenteropancreatic neuroendocrine tumors. And it has been in the last decade or so that there has been more developments in the management of these tumors as well as the understanding of the symptoms related to these tumors. But that said, yes, we do need more therapies for gastroenteropancreatic neuroendocrine tumors. Of the treatment options that we have, we all know in the field that even though we have disease control by using the different options for the systemic management of gastroenteropancreatic neuroendocrine tumors, we need options where we can achieve an objective response, especially for these tumor types. But there is a significant volume of disease and we see a lot of these patients with gastroenteropancreatic neuroendocrine tumors. And now where the field is going is to make some of these therapies more effective, to develop more therapies as well. For example, immunotherapies, a different type of immunotherapy understand the tumor immune microenvironment of these tumors in order to develop therapies as well. From the antibody drug conjugates, I think that's a new way to also address or treat these tumor types, understanding about the different markers found on these tumors that way they can be addressed in different ways. Now with the development of new therapies, I think that's something that can help us as well not only have disease control and as well as having an objective response, but having a better objective response can certainly also help with the symptoms related to hormone excess too. In terms of other therapies, I think some of the issues that we encounter are like the refractory carcinoid diarrhea and how do we manage this. We do have therapies that can help us control the diarrhea in the refractory settings, such as telotristat. Telotristat is one of the newer medications that can help us control the refractory diarrhea. But that said, despite this, that we still encounter situations where it's sometimes difficult to control. I think in those situations it will be good to understand more about the biology of these tumors as well and how we manage. If there is a different time or how do we implement these options. I think there is so much to learn. But that said, I feel we're in hopeful times. We're understanding more about these tumors so that way we can help us develop better therapies not only to have control of the tumor growth as well having control of the symptoms. And it's the same with the pancreas neuroendocrine tumors in the metastatic setting. Sometimes it may be difficult to control this hormone excess. But understanding these and having therapies that can achieve more of an objective response, I think that will definitely help us more and manage these patients. But one aspect I want to mention, and Dr. Perez also mentioned as well, the fact that we have these guidelines that help us understand about the different symptoms related to hormone excess and how to address it, I think is very important because having symptoms related to hormone excess can be detrimental to the quality of life on patients with neuroendocrine tumors that may necessarily be related to disease progression and having this information is so important. And I'm hopeful for the different therapies. There's different clinical trials ongoing for neuroendocrine tumors and especially in the field of PRRT. And a lot of more information will come with the different alpha-PRRT and combination therapy. So more information to come in the next couple of years. So this is, in my opinion, hopeful times for this field. Brittany Harvey: It's great to hear that you're hopeful for all the developments in this field and we'll look forward to the development and discovery of new therapies and further research and then, hopefully incorporate those updates into guidelines in the future. So I want to thank you both so much for your work to develop these guidelines and thank you for your time today. Dr. Del Rivero and Dr. Perez. Dr. Jaydira Del Rivero: Thank you so much for having us. Dr. Kim Perez: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Postpartum hemorrhage is one of the top five causes of maternal mortality—and when it happens, nurses are often the ones who recognize it and initiate prompt treatment. In this episode, we're diving into how to recognize and respond to this high-risk situation with confidence. You'll learn the pathophysiology behind postpartum hemorrhage as well as the major causes so you can know who's most at risk. And, we'll use the LATTE method to break it down like a pro. If you're heading into your OB clinical or prepping for exams, this is an episode you won't want to miss!

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

Not everyone is the right fit for your practice. But when and how do you let them go? In this episode of Practical Solutions Day, Kirk Behrendt brings back Adriana Booth, one of ACT's amazing coaches, to help you see the five signs that it's time to part ways and how to “free up” their future. To learn how to start enjoying the people around you, listen to Episode 884 of The Best Practices Show!Learn More About Adriana:Join Adriana on Facebook: https://www.facebook.com/adriana.boothFollow Adriana on Instagram: https://www.instagram.com/adrimariebSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttSee the ACT Dental/BPA Live Event Schedule: https://www.actdental.com/eventGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 884: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Main Takeaways:Are your team members aligned with your core values?Do your team members consistently fail to meet expectations?Are your team members showing resistance to growth and feedback?Do your team members show toxic behaviors that impact your culture?What negative impact is your team's bad behavior having on your patients?Be prepared to have the “Today is the day” conversation when the time comes.Snippets:0:00 Introduction.3:08 Why this is an important topic.10:35 Misalignment with your core values.15:07...

SPECIAL INBOUND LOGISTICS VIDEO PODCAST SERIES: Inbound Logistics and Xometry take a hard look at the impact of tariffs particularly on cross-border trade. How can your business weather the turmoil and still find ways to thrive? Our special guest is Jose Minarro, Managing Director of Cross-Broder Logistics for Sunset Transportation. See the full video here: https://www.inboundlogistics.com/video-podcasts/ FOR MORE INFORMATION: Sunset Transportation: https://www.sunsettrans.com/ DO YOU WANT TO RESPOND TO THIS EPISODE? Call our Dialog Line: 888-878-3247 DOWNLOAD THE NEW INBOUND LOGISTICS APP featuring the updated and expanded Logistics Planner! Available on iTunes and the Google Play Store: bit.ly/ILMagApp  bit.ly/ILMagAppGoogle Are you a #logistics Thought Leader that would like to be featured on the Inbound Logistics Podcast?  Connect with me on Twitter:  @ILMagPodcast   Email me: podcast@inboundlogistics.com   Connect with Inbound Logistics Magazine on LinkedIn: https://www.linkedin.com/company/inbound-logistics Follow us on Twitter: www.twitter.com/ILMagazine Like us on Facebook: www.facebook.com/InboundLogistics Catch our latest videos on YouTube: www.youtube.com/inboundlogistics   Visit us at www.inboundlogistics.com

Fatenn Mostafa Kanafani has led a life full of twists and turns. Her career trajectory has seen her go from being a successful marketer with Procter & Gamble to being instrumental in the success of the relaunch of Ahram Beverages, leading to its eventual sale to Heineken in 2002. Fatenn then turned her attention to modern Egyptian art and launched Art Talks, a gallery as well as a forum for discussion on all aspects of art. She is now working on a third book in a trilogy looking at Egyptian modern art and artists. She talks to me in great detail about the threads connecting art, politics, and her identity in shaping who she is today. This episode is brought to you by EFG Hermes One, your one app for investing in more than 35 stock markets worldwide. Download EFG Hermes One on the App Store or Google Play Store and start investing today! On a bonus episode out next week, I talk to Fatenn about her work in documenting, codifying, and cataloging her research in art. She's contributed a chapter in the book Daughters of the Nile, authored Modern Art in Egypt, and is now working on a third book. You can find out all about this on the bonus episode, so stay tuned. Chapters: 0:00 On this episode… 2:01 Childhood Experiences Abroad 5:21 Cultural Identity and Challenges 7:29 Transition to Marketing Career 10:36 Journey with Procter & Gamble 13:17 Moving Back to Cairo 18:11 Ahram Beverages 21:56 The Ahram Beverages Success Story 24:08 Personal Life and Marriage 28:34 The Role of Art 29:38 Founding Art Talks 35:50 Focus on Modern Egyptian Art 39:01 Lightening Round Learn more about your ad choices. Visit megaphone.fm/adchoices

How many butts are in your chairs? It's a simple yet overlooked question. In this episode of Metric Mondays, Kirk Behrendt brings back Dr. Barrett Straub, ACT's CEO, to break down capacity and help you identify if and why your chairs aren't full. Stop operating at a deficit — especially without knowing it! To learn how to get capacity to 95%, listen to Episode 883 of The Best Practices Show!Learn More About Dr. Straub:Send Dr. Straub an email: barrett@actdental.com Join Dr. Straub on Facebook: https://www.facebook.com/barrett.d.straubSend Gina an email: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttSee the ACT Dental/BPA Live Event Schedule: https://www.actdental.com/eventGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 883: https://www.youtube.com/@actdental/videosMain Takeaways:Start by analyzing whether your current chairs are being utilized.Use data to identify the factors causing holes in your chairs, not emotion.Your team wants to help you be successful. Help them by giving them a system.Choose a few KPIs to track and get started. You don't need to track them all at once.If you're at 95%, figure out the problem. Is it a scheduling issue or a production issue?Snippets:0:00 Introduction.0:27 Capacity, explained.1:51 The importance of chair utilization.5:00 Identify why you have a money problem.8:29 Actionable tips.11:46 Other KPIs to know.15:33 Last thoughts.Dr. Barrett Straub Bio:Dr. Barrett Straub practices general and sedation dentistry in Port Washington, Wisconsin. He has worked hard to develop his practice into a top-performing, fee-for-service practice that focuses on improving the lives of...

We all want a good lifespan. But what's critical is a good healthspan. In this episode of Clinical Edge Fridays, Dr. Bradley Bale, co-founder of the BaleDoneen Method, shares how dentists can make that happen by implementing their proven methods to prevent cardiovascular events. Help people enjoy life without disease! To learn more about the BaleDoneen Method to prevent and manage chronic diseases, listen to Episode 882 of The Best Practices Show!Learn More About Dr. Bale:Join Dr. Bale on Facebook: https://www.facebook.com/BaleDoneenMethodFollow Dr. Bale on Instagram: https://www.instagram.com/baledoneenLearn more about the BaleDoneen Method: https://baledoneen.comRegister for the BaleDoneen Preceptorship course with code EARLYBIRD (October 9-11, 2025): https://baledoneen.com/provider/bdm-preceptorshipMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttSee the ACT Dental/BPA Live Event Schedule: https://www.actdental.com/eventGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 882: https://www.youtube.com/@actdental/videosRead Beat the Heart Attack Gene by Dr. Bradley Bale and Dr. Amy Doneen: https://baledoneen.com/bdm-booksRead Healthy Heart, Healthy Brain by Dr. Bradley Bale and Dr. Amy Doneen: https://baledoneen.com/bdm-booksMain Takeaways:You can stop arterial disease in anyone.Oral health is a vital component of arterial health.Know the myths of what causes heart attacks and strokes.Oxidative stress is the driver of many diseases....

Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy options for patients based on prior therapy received in the castration-sensitive and non-metastatic castration-resistant settings. He emphasizes personalizing treatment choices for each individual, considering patient-specific symptoms and signs, treatment-related toxicities, potential drug interactions, cost, and access. He also reviews recommendations on response assessment. The conversation wraps up with a discussion of potential future updates to this guideline, as the guideline transitions into a “living guideline” on mCRPC. Read the full guideline update, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update”. Transcript This guideline, clinical tools, and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology.      Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Rohan Garje from Miami Cancer Institute Baptist Health South Florida, lead author on, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Garje. Dr. Rohan Garje: Absolutely. Thank you so much for having me, Brittany. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Garje, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to start on the content of this guideline, first, could you provide us an overview of the purpose of this guideline update? Dr. Rohan Garje: Sure. So ASCO has guidelines for prostate cancer and the specific guideline which we have updated for metastatic castrate-resistant prostate cancer was originally published in 2014. It's almost a decade. It's been a long time due for an update. Over the last decade, we have seen a lot of advances in the treatment of prostate cancer, specifically with regards to genomic testing, newer imaging modalities, and also the treatment landscape. Now we have newer options based on genomic targets such as PARP inhibitors, we have radiopharmaceuticals, a newer variant of chemotherapy, and also some specific indications for immunotherapy which were not addressed previously. Because all these advances have been new, it was really important for us to make an update. In 2022, we did make a rapid update with lutetium-177, but these additional changes which we have seen made it an appropriate time frame for us to proceed with a newer guideline. Brittany Harvey: Absolutely. It's great to hear about all these advances in the field to provide new options. So I'd like to next review the key recommendations from this guideline. So let's start with the overarching principles of practice that the panel outlined. What are these key principles? Dr. Rohan Garje: As a group, all the panel members came up with some ground rules: What are necessary for all our patients who are being treated for metastatic CRPC? First, the founding aspect was a definition for what is metastatic CRPC. So we defined metastatic CRPC as castrate level of testosterone with evidence of either new or progressive metastatic disease on radiological assessments or patients who have two consecutive rising PSAs in the setting of existing metastatic disease. We also emphasized on the need for germline and somatic testing for patients with metastatic prostate cancer at an earliest available opportunity because it is critical to select appropriate treatment and also right treatment for patients at the right time. And we actually have a concurrent guideline which addresses what genes to be tested and the timing. The other principles are patients should continue to receive androgen deprivation therapy or undergo surgical castration to maintain castrate level of testosterone. Now the key aspect with these guidelines is personalizing treatment choices. As you can see the evolution of treatment options for prostate cancer, the drugs that were initially developed and approved for prostate cancer were primarily in castrate-resistant settings, but now most of these drugs are being utilized in castrate-sensitive. So, when these patients develop castration resistance, the challenges are there are no appropriate particular drug-specific guidelines they meet. So, it's very important for the clinicians to be aware of what treatments have been received so far prior to castration resistance so that they can tailor the treatment to patient specific situations. In addition, prior to choosing a therapy, it is important for the physicians to consider patient specific symptoms or signs, treatment-related toxicities, potential drug interactions, cost, and also access to the drugs. There may be multiple treatment options available for the patients, but for a patient specific scenario, there may be a drug that may be more promising than the others. So, it is important to tailor the drug choices based on patients' unique circumstances. The panel also recommends to early integrate palliative and supportive care teams for symptom management and also discuss goals of care with the patient as each patient may have unique needs and it's important for physicians to address those concerns upfront in the care. The panel also suggests patients to receive RANK ligand inhibitors such as denosumab or bisphosphonates such as zoledronic acid to maintain the bone strength to prevent skeletal-related events. Finally, I would like to also emphasize this point about the lack of randomized clinical trial data for optimal sequencing of therapies for patients with metastatic CRPC. As I previously alluded, we have taken into account all ongoing clinical trials, prior published data, and came up with a format of preferred drugs based on prior treatments and, I think, by following these several clinical principles which I just mentioned, we can optimally choose and utilize best treatments for patients with metastatic CRPC. Brittany Harvey: Absolutely. These principles that you just outlined are important for optimal patient care, and then I want to touch on one of those things. You talked importantly about the treatments received so far. So in the next set of recommendations, the role of systemic therapy was stratified by the prior therapy received in the castration-sensitive and non-metastatic castration-resistant setting. So starting with what does the panel recommend for patients who are previously treated with androgen deprivation therapy alone in these previous settings and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: There are multiple treatment options based on prior treatment received. So for patients who received only ADT for their castration-sensitive disease, the panel strongly urges to get HRR testing to check for homologous recombinant repair related changes, specifically for BRCA1 and BRCA2 mutations, because we have three studies which have really shown significant clinical benefit for patients who have BRCA1 and BRCA2 mutations with drugs such as the combination of talazoparib and enzalutamide or olaparib with abiraterone or niraparib with abiraterone. Unless we test for those mutations, we'll not be able to give these agents upfront for the patients. In the HRR testing, if patients have HRR alterations but they are in genes which are non-BRCA, the guideline panel recommends to utilize talazoparib and enzalutamide based combination therapies. Now, if they don't have HRR alterations then there are multiple treatment choices available. It could either include androgen receptor pathway inhibitors such as abiraterone with prednisone. We could also consider docetaxel chemotherapy. The alternate choices for androgen receptor pathways include enzalutamide or the newer agents such as apalutamide and docetaxel. So, as you can see there are multiple options available, but the panel definitely emphasizes to test for HRR testing because this gives patients access to more precision therapies at this point. There may be various scenarios where a unique drug may be available for a specific patient situation. For example, patients who have very limited disease burden and may have one or two metastatic lesions, after a multidisciplinary discussion, targeted local therapies such as radiation or potentially surgery could also be offered. In select patients who have very indolent disease where they are castrate-resistant based on slow rising PSA, low-volume disease or asymptomatic disease can consider sipuleucel-T. And in patients who have bone-only metastatic disease, we could also consider radium-223, which is primarily now utilized for patients who have symptomatic bone disease. Brittany Harvey: Great. I appreciate you reviewing all those options and talking about how important it is to tailor treatment to the individual patient. So then the next category of patients, what is recommended for those who have been previously treated with ADT and an androgen receptor pathway inhibitor and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: So for patients who received ADT along with an androgen receptor pathway inhibitor, which we consider would be a most common cohort because most patients now in castration-sensitive setting are receiving androgen receptor pathway inhibitor. It was different in the past where five or six years back ADT alone was the most common treatment, but fortunately, with enough awareness and education, treatment choices have improved. Patients are now receiving ADT and ARPI as the most common choice of drug. Once again, at this point the panel emphasizes to consider HRR testing in there is enough data for us to suggest that patients who have alterations in the HRR pathway definitely will benefit with the PARP inhibitor. You know the multiple options, but specifically we speak about olaparib. And then if they are HRR-negative, we prefer patients receive agents such as docetaxel or if they are intolerant to docetaxel, consider cabazitaxel chemotherapy, options such as radium-223, and if they have a specific scenario such as MSI-high or mismatch repair deficiency, pembrolizumab could also be considered. The panel also discussed about the role of a second ARPI agent. For example, if patients progressed on one androgen receptor pathway inhibitor, the second androgen receptor pathway inhibitor may not be effective and the panel suggests to utilize alternate options before considering androgen receptor pathway inhibitor. There may be specific scenarios where a second ARPI may be meaningful, specifically, if alternate choices are not feasible for the concern of side effects or toxicities or lack of access, then a potential ARPI could be considered after progression on ARPI, but the panel definitely encourages to utilize alternate options first. Brittany Harvey: Great. Thank you for outlining those options as well for those patients. So then the next category, what is recommended for patients who have been previously treated with ADT and docetaxel? Dr. Rohan Garje: For patients who received ADT and docetaxel and were never treated with androgen receptor pathway inhibitors, the panel again emphasizes on HRR testing. If they have BRCA1 and 2 mutations, the combination therapies of talazoparib with enzalutamide, olaparib with abiraterone, or niraparib with abiraterone are all good choices. If they don't have BRCA mutations but they have other HRR mutations, the panel suggests to potentially utilize talazoparib with enzalutamide. And if they do not have any HRR alterations, the options could include androgen receptor pathway inhibitors such as abiraterone or enzalutamide. I want to emphasize that these are preferred options, but not the only options. As you can see, there are multiple options available for a particular clinical situation - so the ability of the physicians to access particular combinations, the familiarity of those drugs or the patient's unique situation where they have other medications which can potentially interact with a choice of agents. So I think based on access, based on cost and patients' concurrent illness with potential drug interactions can make one particular combination of therapy better over the other options. Brittany Harvey: Absolutely. That's key to keep in mind that access, contraindications, and cost all play a role here. So then the next set of recommendations. What are the key recommendations for patients who have previously been treated with ADT, an androgen receptor pathway inhibitor, and docetaxel who now have mCRPC? Dr. Rohan Garje: Yes. In this group, the options remain, again, broad. We utilize PSMA imaging here specifically and if they are positive on PSMA imaging, lutetium-177 is a good option. If they do not have PSMA-positive disease on PSMA imaging but if they have HRR alterations, olaparib could be utilized. And if they are negative on PSA imaging, they don't have HRR alterations, then alternate options could include cabazitaxel, radium-223. And if they have MSI-high or deficiency in mismatch repair, pembrolizumab could be utilized in this setting. Brittany Harvey: Thank you for outlining those options as well. So then next the panel addressed treatment options for de novo or treatment emergent small cell neuroendocrine carcinoma of the prostate. What are those key recommendations? Dr. Rohan Garje: Yes. This is a very high unmet need group because there are limited clinical trials, especially prospective clinical trials addressing treatment options for this group. Most of our current guidelines are always an extrapolation from lung small cell cancer based guidelines, but the panel recommends to utilize cisplatin or carboplatin along with etoposide as a preferred choice for this group. Also, an alternate option of carboplatin along with cabazitaxel could be considered for this cohort. The panel also encourages participation in clinical trials. There are numerous trials ongoing now in smaller phase studies and I think it's important for patients to consider these trials as well, because this will give them access to newer agents with potential biological targets. In addition to these agents in specific scenarios or potentially case by case basis, because we don't have prospective data, so we have made it as a select case by case basis to consider adding immunotherapy along with platinum-based chemotherapy followed by maintenance immunotherapy, which is currently a standard of care in small cell lung cancer. But the data is so limited in prostate cancer, so the panel suggested that it has to be a case by case basis only. The alternate options also include lurbinectedin, topotecan, tarlatamab upon progression on platinum-based chemotherapy. Brittany Harvey: Yes. It's important to have these recommendations in these unique situations where there is really a lack of data. So then the final set of recommendations I'd like to cover, what does the panel recommend for how clinicians should assess for response while patients are on systemic therapy and what scans are recommended for this response assessment? Dr. Rohan Garje: Yes. Again, this is another strong emphasis of the panel for global assessment of the patients. Traditionally, patients and physicians per se are heavily reliant on PSA as an accurate marker for response. This is in fact true in earlier phases of prostate cancer either in castrate-sensitive setting or localized prostate cancer setting. But as patients evolve into castrate-resistant, we don't want to heavily rely on PSA alone as a marker of response. The panel suggests to incorporate clinical response, radiological response, and also include PSA as a component, but not just rely primarily on PSA. So the panel also suggests that patients should get a bone scan and a CT scan every three to six months while on treatment to assess for appropriate response or for progression. And now one key important aspect, we are all aware about the evolving role of PSMA-based imaging with several of these new agents that are currently available. We do acknowledge these scans definitely have an important role in the care for patients with metastatic prostate cancer. Currently, the utility is primarily to select patients for lutetium-based therapy and also in situations where the traditional scans such as technitium 99 bone scan or CT scan are equivocal, then a PSMA-based imaging can be helpful. Now we are also aware that there are newer studies coming up, prospective data coming up for the role of PSMA-based imaging for response assessment. We are hoping to update the guidelines if we get access to newer data, but currently we have not recommended the utility of PSMA-based imaging for response assessments. Brittany Harvey: Understood. And I appreciate you describing where there is data here and where there's a lack of data to currently recommend. And we'll look forward to future updates of this guideline. Coming back to – at the start you mentioned how much has changed since the last guideline update. So Dr. Garje, in your view, what is the importance of this update and how will it impact both clinicians and patients with metastatic castration-resistant prostate cancer? Dr. Rohan Garje: The updated guidelines are designed to have a significant impact on clinical practice and also patient outcomes by providing clinicians with a comprehensive evidence-based framework for managing patients with metastatic CRPC. And also, by using these guidelines can make informed decisions, can select therapies tailored to patients' unique genomic status, clinical situation, where they are in the course of the cancer based on what they received previously. Also utilizing these guidelines, we can potentially improve patient outcomes, improve survival, and importantly have efficient use of healthcare resources. Brittany Harvey: Absolutely. We're always looking for ways to improve patient outcomes and survival. I want to wrap us up by talking a little bit about the outstanding questions in this field. So earlier you had mentioned about prospective data to come about PSMA PET scans, but what other outstanding questions are there for patients with metastatic castration-resistant prostate cancer? And what evidence is the panel looking forward to for future updates? Dr. Rohan Garje: We do have now rapidly evolving data specifically about the utility of the radiopharmaceutical lutetium-177 prior to chemotherapy. We are hoping that with newer data we can make some changes to the guideline based on that. We are also looking at newer drugs that are coming up in the pipeline, for example, androgen receptor degraders. We are looking at data that might potentially help based on bispecific T-cell engagers and newer radiopharmaceuticals. So I think in the next few years, we will definitely update all the guidelines again. But this time we are trying to do it more proactively. We are following a newer model. We are calling it as ‘living guidelines' where we are actually utilizing week by week updates where we look at the literature and see if there is any potential practice impacting change or publication that comes up. And we are trying to incorporate those changes as soon as they are available. That way patients and practicing physicians can get the latest information available through the guidelines as well. Brittany Harvey: That's great to hear. Yes, we'll await this data that you mentioned to continuously update this guideline and continue to improve patient outcomes for the future. So Dr. Garje, I want to thank you so much for your time to update this guideline. It was certainly a large amount of recommendations, and thank you for your time today, too. Dr. Rohan Garje: Thank you so much for having me here. And it's always nice talking to you. Brittany Harvey: And finally, thank you to our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

The rivalries in New York have been distinct between the two MLS branches in the Big Apple. However, FC Cincinnati has taken a few bites out of the core before as well. We've already covered the bile between Cincinnati and the Red Bulls, and this week we take on the bluer side of the 5 Boroughs. Last season, it ended a bit sour with New York City FC marching into TQL Stadium and winning the rubber match to knock the Orange & Blue out of the playoffs. While Cincinnati brought in a ton of big-money talent in the offseason, NYCFC did the opposite by staying pat. The only major change came at the head coach role, with Nick Cushing exiting and Pascal Jansen taking over. How has that big change worked so far in New York? We invite Andrew from Hudson River Blue back to talk about the Pigeons and perhaps give us a few insights on visiting Citi Field for a match. (Perhaps he has a recommendation for matzo ball soup?) Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Host Jeremy C. Park talks with Dr. Holly Roselle, CEO and Co-Founder of ForceField Protection, along with her husband, Charles Roselle, COO and Co-Founder, who both discuss their backgrounds with extensive experience in security and performance psychology and the technology they created that protects and connects lone workers, particularly those in home health care. Charles Roselle served as a United States Secret Service Agent for 16 years and Dr. Holly Roselle was a human performance specialist with military special operations. Charles devoted his career to protecting others and Holly worked with military service members on techniques to stay motivated, productive, and enjoy performing at their best. More personally, they both experienced the underlying fear and anxiety of going into unknown homes and environments during their work. Together, with a team of top developers, they have used their experiences to create an app that helps protect and connect lone workers so they are safer and more productive.During the interview, Holly and Charles highlight the vulnerability of lone workers and the need for protection, touching on the high crime rates and assault rates faced by these workers. They discuss the technology and app, which allows users to check in and out of locations, with automatic notifications sent to emergency contacts. A unique feature of the app is its "touchless distress" feature, which signals distress without the user needing to call or text. This feature is patented and differentiates their product from others in the market. They talk about some of the many ROI benefits of the app, including enhanced productivity, employee engagement, accountability, and safety with employees feeling more valued and protected.The conversation concludes talking about next steps as Holly explains that businesses can email them for a 30-day free trial, which allows them to upload a certain number of employees and test the system. Charles and Holly also mentioned that they have a consumer app available for download on the Google Play Store and Apple Store, which is perfect for individuals and families, runners, and others who want to access the apps features to keep loved ones informed of their activities and whereabouts. Holly and Charles also offer demos and assistance with employee onboarding for businesses interested in the app.Visit https://forcefieldnow.com to learn more about ForceField Protection and their ForceField Protection Personal Safety App.info@forcefieldnow.com888-LONEAPP

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can improve your handling of "Aerial Service" as a goalkeeper. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

When you don't have alignment, bad things happen. In this episode of Practical Solutions Day, Kirk Behrendt brings back Heather Crockett, one of ACT's amazing coaches, to share three hacks to prevent misalignment and burnout from happening in your practice. To learn how to proactively keep your team aligned, listen to Episode 881 of The Best Practices Show!Learn More About Heather:Send Heather an email: heather@actdental.com Join Heather on Facebook: https://www.facebook.com/heather.r.crockettFollow Heather on ACT's Instagram: https://www.instagram.com/actdentalEmail ACT for the CRO tool and checklist: info@actdental.com Send Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttSee the ACT Dental/BPA Live Event Schedule: https://www.actdental.com/eventGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 881: https://www.youtube.com/@actdental/videosWatch “How Should a Company Share Its Values?” by Simon Sinek: https://www.youtube.com/watch?v=5yE541BY-1cMain Takeaways:Misalignment is the root of all evil.Establish consistent communication rhythms.Document your core values and make them visible.Find creative, engaging ways of celebrating your core values.Lead by example. What message do you want to show your team?Snippets:0:00 Introduction.2:22 Why this is an important topic.4:53 Alignment is a big deal.7:36 Document...

Dr. Nimish Mohile and Dr. Jaishri Blakeley share the new rapid recommendation update to the therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline. They review the evidence from the INDIGO trial that prompted this update, and how to incorporate the use of vorasidenib into clinical practice. They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest update, “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.” Transcript This guideline, clinical tools, and resources are available at http://www.asco.org/neurooncology-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in Journal of Clinical Oncology.   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jaishri Blakeley from Johns Hopkins University School of Medicine and Dr. Nimish Mohile from the Department of Neurology and Wilmot Cancer Institute at the University of Rochester Medical Center, co-chairs on “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: American Society of Clinical Oncology-Society for Neuro-Oncology Guideline Rapid Recommendation Update.”  Thank you for being here today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you.  Dr. Nimish Mohile: Thank you for having us.  Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Blakeley and Dr. Mohile who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.   So then, to jump into the content here, Dr. Mohile, could you start us off by describing what prompted this rapid update to the ASCO-SNO therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline, which was previously published in 2021?  Dr. Nimish Mohile: Yeah. So the key reason for this update is the publication of a study in 2023. And this was a study called the INDIGO study that looked at a new class of therapies, something called IDH inhibitors. And in this study with a drug called vorasidenib, changed how we think about the treatment of oligodendrogliomas and astrocytomas, so particularly the grade 2 oligodendrogliomas and grade 2 astrocytomas. Because of the results of that study, we decided that we needed to do an update to inform clinicians about some of these changes and how we might approach these tumors differently today.  Brittany Harvey: Great. I appreciate that background. So then, based off the new data from the INDIGO study, what are the updated and new recommendations from the expert panel?  Dr. Nimish Mohile: So the key findings from the INDIGO study involved people who had grade 2 astrocytomas and grade 2 oligodendrogliomas. And in the setting after surgery, they were treated with vorasidenib, and what they found is that this delayed the time to next intervention. And the key aspect of that is that it delayed when we could start radiation and chemotherapy in these patients.   So what we did in the guidelines is that for both low grade oligodendrogliomas and low grade astrocytomas, we added one additional guideline statement. Our previous guideline in 2021 offered the options for observation or treatment with radiation and chemotherapy. And now in this guideline, we have options for observation, treatment with vorasidenib in those in whom we feel it is safe to defer radiation and chemotherapy, and then treatment with radiation and chemotherapy. So we've added in an additional option here. And the key message of the guideline is really on how, as clinicians, we think about using the vorasidenib and what the ideal setting for using the vorasidenib is.  Brittany Harvey: Excellent. It's great to hear about this new option for patients. So then you were just talking about how we think about who to offer this IDH inhibitor to. So, Dr. Blakeley, what should clinicians know as they implement these new recommendations into practice?  Dr. Jaishri Blakeley: Yes. So, first and foremost, let's go back to 2021, and a key note from those guidelines was the importance of molecular testing. And at that point, the importance of molecular testing, which in large part was focused on IDH1 or IDH2 mutations, was prognostic. We could say there's a difference in an IDH1 mutant astrocytoma and an IDH1 wild type astrocytoma, but we didn't have a specific therapeutic recommendation attached to that, like Dr. Mohile just said. And the big shift here is now we have a specific therapeutic for that population with IDH1 or IDH2 mutant glioma.   So for clinicians, we hope that they've been getting molecular testing on newly diagnosed glioma already, but now there's an additional motivation to do so because it may change your treatment plan in the right circumstance. So since the publication of the phase III INDIGO study that Dr. Mohile mentioned, and the FDA approval of vorasidenib, if you meet the specified criteria in the clinical trial - which the guidelines point out is a little different than what's on the FDA label, so clinicians might want to dig into that a little bit - then there is a treatment option that is new and different than combined chemoradiation or radiation alone or observation.  Brittany Harvey: I appreciate those clarifications there.   So then also, Dr. Blakeley, how does this update impact patients with astrocytic or oligodendroglial tumors?  Dr. Jaishri Blakeley: So first, patients also should know if they have IDH mutant gliomas. And this update only applies to people with IDH1/2 mutant glioma. Perhaps, we're not sure, it might only apply to people who are in the newly or newly-ish diagnosed category because the INDIGO study required that people were within the first five years of their surgical diagnosis and had not had other treatment. So there are a lot of people who have astrocytoma or oligodendroglioma who may or may not know their IDH1/2 status and may have already had another therapy - this update doesn't apply to them. We hope that future research will teach us about that. This update is for people who are newly diagnosed and just starting the journey to figure out the best therapy. It does say that if you do have that IDH1/2 alteration in your tumor, there is a drug therapy that is different from the drug therapies we would offer gliomas that do not have the IDH1/2 mutation.  Brittany Harvey: Absolutely. I think both that emphasis on molecular testing is very important and also thinking about that study inclusion criteria and how it impacts who's eligible for this treatment.   So then finally, Dr. Mohile, what are the outstanding questions about vorasidenib or other interventions for gliomas in adults?  Dr. Nimish Mohile: I think the key question for clinicians is exactly who we're going to use this in. The challenges with inclusion criteria in clinical trials is they don't actually always match what we're seeing in the clinic. And I think it brings up the question of, in low grade oligodendrogliomas which we think of as very slow growing tumors, do we have the option outside of the strict inclusion criteria to use that drug in other settings? I think it brings up the question for some clinicians in some of the higher grade tumors, in the grade 3 tumors, we don't yet have data in that area and our guideline doesn't address that. But I think some will be asking what the clinical activity of vorasidenib is in that setting. There are some suggestions that the IDH inhibitors may impact seizure control, and I think that that's data that we're continuing to wait on.   So I think that there's several outstanding questions there that we will have answers for hopefully in the next several years. I think the big question that we don't have an answer for and that will take a long time to know is whether the addition of vorasidenib in this setting actually improves how long people live. And given how long people with low grade oligodendrogliomas and low grade astrocytomas live today, we probably won't have an answer to that question for more than a decade.  Brittany Harvey: Definitely. We'll look forward to these ongoing developments and eventually longer term data on overall survival on these agents.   So, I want to thank you both so much for your work to rapidly include this information from this new trial. And thank you for your time today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you so much.  Dr. Nimish Mohile: Thank you Brittany.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/neurooncology-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. 

You feel like you should be producing more. But just doing more isn't the answer! In this episode of Metric Mondays, Kirk Behrendt brings back Dr. Barrett Straub, ACT's CEO, to break down the one basic equation you need to know to produce more while working less. Stop spending 220 days at the office! To learn how to produce more the right way, listen to Episode 880 of The Best Practices Show!Learn More About Dr. Straub:Send Dr. Straub an email: barrett@actdental.com Join Dr. Straub on Facebook: https://www.facebook.com/barrett.d.straubSend Gina an email: gina@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttSee the ACT Dental/BPA Live Event Schedule: https://www.actdental.com/eventGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 880: https://www.youtube.com/@actdental/videosMain Takeaways:Working more days is not the answer.Make decisions with data, not with emotions.Learn the equation to calculate gross production.Snippets:0:00 Introduction.1:34 Why this is an important topic.2:48 Why emotion comes into this equation.3:49 The formula for gross production.7:06 Two key numbers to pull.12:35 Time is the new rich.14:21 Final thoughts.Dr. Barrett Straub Bio:Dr. Barrett Straub practices general and sedation dentistry in Port Washington, Wisconsin. He has worked hard to develop his practice into a top-performing, fee-for-service practice that focuses on improving the lives of patients through dentistry.A graduate of Marquette Dental School, Dr. Straub's advanced training and CE includes work at the Spear Institute, LVI, DOCS, and as a member of the Milwaukee Study Club. He is a past member of the Wisconsin Dental Association Board...

There's nothing like that moment when your patient starts having periods of obstructive apnea and you realize…YOU are the airway. In this episode, I'm walking you through the key things you need to know so you can feel more confident (and hopefully a bit less terrified) managing soft tissue obstructions. Hit play on this episode and I'll talk you through the signs of obstruction, optimal positioning, and the proper use of airway adjuncts like the OPA and NPA. If airway management has ever made you a little nervous, this episode is for you. ___________________ Full Transcript - Read the article and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Study Sesh - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  Med Surg Solution - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides.  Crucial Concepts Bootcamp - Start nursing school ahead of the game, or reset after a difficult first semester with my nursing school prep course, Crucial Concepts Bootcamp. Learn key foundation concepts, organization and time management, dosage calculations, and so much more. Straight A Nursing App - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store.

The Peter Vermes era has come to an end in the KCK. Sporting Kansas City now has to seek a new identity for the first time in 16 years. The new coach bounce was pretty big last week in San Jose, but is there a future under interim leadership? This is no longer the team led by an experienced goalkeeper between the posts. We invited Jimmy and Daniel from the No Other Pod podcast to discuss this brave new world for SKC. Now that the old guard has left, who pilots the offense? What changes are coming with the end of the trade window? How much of the rocket fuel in last Saturday's win is still in the tank against a Cincinnati squad starting to find their footing? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

They are numerous. They are patient. They are COMING for the United States in droves this spring: They are cicadas. *The* Cicada guy Dr. Gene Kritsky joins to chat all about the annual cicadas you may see every summer vs. the periodical ones that cycle through the states in broods of giant numbers. Learn how they survive underground for decades, what they are doing down there, and all about their lifecycle. Plus, get inspired to take a cicada safari and appreciate their songs, which can be as loud as an ambulance. By the end, you'll want to don a bug costume and take a road trip to witness Brood XIV's emergence this spring!Dr. Gene Kritsky's new cicada book The Pilgrims' Promise: The 2025 Emergence of the Periodical Cicada Brood XIVDownload the Cicada Safari app at the Apple Store or Google Play Store.Check out Dr. Kritsky's websiteAlso see CicadaMania.com, and follow them on InstagramA donation was made to Mount Saint Joseph's cicada research in the School of Behavioral and Natural SciencesFull-length (*not* G-rated) Cicadology episode + tons of science linksBecome a patron of Ologies for as little as a buck a monthOlogiesMerch.com has hats, shirts, hoodies, totes!Follow Ologies on Instagram and BlueskyFollow Alie Ward on Instagram and TikTokSound editing by Mercedes Maitland of Maitland Audio Productions, Jarrett Sleeper of MindJam Media, and Steven Ray MorrisMade possible by work from Noel Dilworth, Susan Hale, Jacob Chaffee, Kelly R. Dwyer, Aveline Malek and Erin TalbertSmologies theme song by Harold Malcolm

After A Week Off (Thanks All For Sharing Your Well Wishes Regarding The Union Staff Member) We are back! The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can become a better goalkeeper coach. Great listen for young coaches! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

Can better sex save your marriage?

Share with us what you think about UncommonTEEN! I do read your fanmail, but can't message you back! Chat with me at UncommonTEEN.com!Whether you have given your life to the Lord recently OR you gave your life to the Lord when you were younger and walked away from God OR you have been faithfully serving God for a while, this episode is for you!  Going all in with Jesus is super important, not just to me, but to God! John 1:12, when you received Jesus as your Lord, you became a child of God, a daughter of the Most High King. God thinks of you as His daughter, and He's committed to being a good Father to you. Luke 10:20, God actually wrote your name in heaven. Many times, we can feel like we've been overlooked, but God knows you! Your name is known in heaven. You are known by the Creator of the universe!2 Corinthians 5:17, when you got saved, you became a new creation! From the inside, your heart and your spirit have been made known to God. You have been forgiven. You have a plan that you were created for that you were created to fulfill on this earth. You were not just created to exist! Ephesians 2:10, while you are God's special creation, you were also created for good works. Jeremiah 29:11, God's plans for you are good and not evil. You don't have to spend the rest of your life trying to figure life out. Next Steps:1.    Water Baptism- after you have made Jesus Lord, this is a way to show publicly what God has already done for you on the inside of you.2.    6 Steps to Discipleship- apply these immediately, but don't expect perfectionSpend time in the Bible daily.Spend time in prayer daily. Get connected in a good Bible-based church, a church that teaches the Word of God and is full of life, that emphasizes a relationship with Jesus Christ.When you mess up, run to God! Make that your first response. He is still your answer. Do life with others who are following Jesus. Tell others what God has done in your life. The goal of these steps isn't perfection, but growth with God. When you receive Jesus, God Almighty now lives inside of you! Ladies, we have some exciting news! The SOAR Community is now FREE!! All you have to do to see if SOAR is right for you is grab your parents, tell them why you are excited about SOAR, and while you still have them with you, go to uncommonteen.com/coaching and click on the application under SOAR and fill it out! **There are limited spots available. ***At this time, SOAR is only open to teen girls 13-17 in the United States. You are beautiful! You are valuable!Your beauty and your value don't change, Even if someone fails to seeHow incredible God made you!Don't forget to head on over to uncommonTEEN.com/coaching and fill our your SOAR Application today!The UncommonTEEN App is still in review on both the Apple Store and the Google Play Store! It looks like Google is going to take a bit longer, but the Apple App should be coming very soon!To ask questions for an upcoming podcast episode or if you need prayer, go to UncommonTEEN.com.For the Ask Me Anything Questions, click on the RED BUTTON at the top of the screen. These questions may used on a future episode of the UncommonTEEN Podcast!For any prayer requests or more personal questions, click on the YELLOW CHAT TAB at the bottom right-hand corner of the screen. These will not be used on the podcast. Connect with Us!Website: UncommonTEEN.comInstagram: @uncommon.teen